Drmić Ana, Saccà Riccardo, Vetter Thorsten, Ehmann Falk
Independent Researcher, Strasbourg, France.
Faculty of Health, Medicine and Life Sciences (FHLM), Maastricht, Netherlands.
Front Pharmacol. 2024 Nov 14;15:1470908. doi: 10.3389/fphar.2024.1470908. eCollection 2024.
The EMA Qualification of Novel Methodologies procedure qualifies methods, technologies and methodologies within a well-defined context of use in a pharma R&D context based on the evaluation of the presented scientific rationale and submitted data. This policy brief analyses QoNM submissions providing policy messages and recommendations to stakeholders on how to better prepare qualification applications in this regard. The recommendations include: 1. Grounding validation strategy using a current standard measure or a distribution technique. 2. Accurately represent pertinent subgroups via accurate inclusion and exclusion criteria. 3. Establish a well-defined and specific CoU with clear descriptions of the use within a development program target population and disease stage. Lastly, it emphasizes role of the QoNM procedure in advancing medicine development methodologies within the EU.
欧洲药品管理局(EMA)的新方法学鉴定程序基于对所提供的科学原理和提交数据的评估,在制药研发背景下明确界定的使用范围内,对方法、技术和方法学进行鉴定。本政策简报分析了新方法学鉴定(QoNM)的申请情况,向利益相关者提供政策信息和建议,说明如何在这方面更好地准备鉴定申请。这些建议包括:1. 使用当前标准测量方法或分布技术来奠定验证策略的基础。2. 通过准确的纳入和排除标准准确代表相关亚组。3. 建立一个明确且具体的使用范围(CoU),清晰描述在开发项目目标人群和疾病阶段内的使用情况。最后,它强调了新方法学鉴定程序在推进欧盟医学开发方法学方面的作用。